Incidences of cardiovascular diseases (CVD) are high among virologically suppressed HIVinfected individuals. Monocyte activation and trafficking are key mechanisms in the evolution of CVD. We studied the ability of cenicriviroc (CVC), a dual C-C chemokine receptor type 2 (CCR2) and CCR5 antagonist, to influence the migration of monocytes from HIV-infected individuals on antiretroviral therapy (ART). Monocytes were derived from 23 ART-suppressed HIV-infected and 16 HIV-uninfected donors. In a trans-endothelial migration model, monocytes, and human aortic endothelial cells (HAoECs) were exposed to cenicriviroc and migrated monocytes, quantified.
INTRODUCTION
Although current HIV combination antiretroviral therapies (ART) have prolonged life expectancy in HIV-infected individuals, the prevalence of non-AIDS-related chronic complications persists, such as HIVassociated neurocognitive disorders (HAND) 1,2 and cardiovascular diseases (CVD). 3, 4 CVD risk is increased in HIV, as HIV-infected persons are 2-fold more likely to develop CVD compared to uninfected individuals. [5] [6] [7] While the underlying mechanisms leading to the clinical observations of CVD are likely multifactorial, [8] [9] [10] [11] [12] [13] immune activation and inflammation, driven in part by monocytes and macrophages, are believed to be a key contributor to the unique pathophysiology of CVD that develops in HIV-infected individuals. [14] [15] [16] [17] [18] [19] During atherosclerosis development and progression, monocytes migrate through the endothelium into the subendothelial space and differentiate into macrophages. [20] [21] [22] There, the accumulation of macrophages leads to foam cell formation and secretion of proatherogenic factors such as chemokines and cytokines. 20, 23, 24 The process of trans-endothelial migration is a multistep process: monocytes first tether and loosely roll along the vessel by binding to selectins on the surface of the endothelium. [25] [26] [27] Firm adhesions are then created at the vascular surface between integrin expressing monocytes and vascular cell adhesion molecule 1 (VCAM-1) and intercellular (I)CAM-1 on the endothelial layer. [28] [29] [30] Diapedesis finally follows, where adhesion molecules such as platelet endothelial cell adhesion molecule (PECAM-1) and CD99 are involved. [31] [32] [33] [34] Whether or not HIV-infection of monocytes/macrophages affects one or more of the steps from rolling to diapedesis has not been clearly defined.
Atherosclerosis and HIV studies utilizing pharmacological inhibitors that antagonize chemokine receptors (CKRs) have not only highlighted pathways that are important in monocyte migration, but have also demonstrated that CKR blockades are an effective strategy to improve disease state. In an apolipoprotein E (ApoE) knockout mouse model, the use of C-C chemokine receptor type 2 (CCR2) pharmacological inhibitors, GSK1344386B, 35 and TLK-19705, 36 decreased macrophage infiltration and atherosclerotic lesion size, respectively. Antagonizing CCR5 has also been successful in reducing atherosclerosis development and progression by blocking inflammatory cell infiltration in both a low density lipoprotein receptor-deficient murine model and in a ritonavir atherosclerosis murine model by treating the animals with TAK-779 37 and maraviroc (an approved HIV ART drug), 38 respectively. Clinical trials involving CCR5 antagonism have yielded variable results. We and others have reported that maraviroc has positive effects in the setting of HAND, as evidenced by improvements in neurocognitive testing performance scores. 39, 40 These effects were likely due, in part, to the ability of maraviroc to inhibit HIV entry into cells, and to reduce monocyte migration and immune inflammation, including monocyte activation. 39, [41] [42] [43] Other studies however have described either no changes in inflammatory parameters such as T cell activation 44, 45 or increases in inflammation, namely T cell and monocyte activation with maraviroc intensification. 45, 46 Given the findings of single blockade of either CCR2 or CCR5 as well as the redundancy and compensatory mechanisms between the various CKRs and chemokine ligands, 47 targeting both CKRs may be more effective than antagonizing a single CKR to inhibit migration and inflammation, and potentially impede HIV-associated CVD development and/or progression. As proof of concept of the benefit of targeting multiple CKRs, administrating the CCR5 antagonist, Met-CCR5, to an atherosclerosis mouse model with combined deficiencies of ApoE, MCP-1, and CX3CR1 led to less atherosclerotic lesion development and monocyte/macrophage migration compared to single chemokine receptor targeting. 48 Cenicriviroc (CVC) is an oral, dual CCR2 and CCR5 antagonist with nanomolar potency and long plasma half-life. [49] [50] [51] CVC has completed Phase 2b development in HIV (NCT01338883) 52 where it was shown to decrease HIV viremia and sCD14 levels (marker of monocyte/macrophage activation) in ART naïve HIV-infected individuals. CVC has also been shown, ex vivo, to decrease HIV entry in peripheral blood mononuclear cells (PBMCs). 53 Additionally, CVC is currently in Phase 3 evaluation for treatment of liver fibrosis in adults with nonalcoholic steatohepatitis (NASH; NCT03028740). The results of the Year 1 primary analysis of the Phase 2b CENTAUR study 652-2-203 (NCT02217475) 54 showed that CVC was well tolerated and resulted in twice as many subjects achieving ≥1 stage improvement in fibrosis and no worsening of steatohepatitis versus placebo in the intention to treat population. 55 CVC has also demonstrated antifibrotic activity in animal models of liver disease, which was largely attributed to decreased monocyte/macrophage infiltration in the liver following hepatocyte injury. [56] [57] [58] We hypothesize that blocking a combination of CKRs will inhibit monocyte activation and trafficking, and ultimately provide a therapeutic strategy to decrease HIV-related CVD.
MATERIALS AND METHODS

Cohort description
This ex vivo study utilized freshly isolated PBMCs from 23 chronically HIV-infected individuals on virally suppressive combination ART who participated in the Hawaii Aging with HIV-CVD cohort study.
Ninety one percent of the participants were male, with a median age of 55 years (interquartile range (IQR)) 25th-75th percentile [51, 57] , a median CD4 count of 689 cells/mm 3 [519, 782] and all had a HIV viral load of <20 copies/ml. Of the 23 participants, 100% were on nucleoside reverse transcriptase inhibitors (NRTIs), 43% on non-nucleoside reverse transcriptase inhibitors (NNRTIs), 22% were on protease inhibitors (PIs) and 48% were on integrase inhibitors (INSTIs). More specifically, 10 were on dual NRTIs (either tenofovir/emtricitabine or abacavir/emtricitabine) and one INSTI (dolutegravir, elvitegravir, or raltegravir); 6 were on dual NRTIs (tenofovir/emtricitabine or abacavir/lamivudine) and one NNRTI (efavirenz or rilpivirine); 2 were on dual NRTIs (tenofovir/emtricitabine) and dual PIs (atazanavir/ritonavir). The other five participants were on less common regimens consisting of a triple NRTIs (tenofovir, emtricitabine, abacavir) plus a PI (efavirenz); triple NRTIs (tenofovir, emtricitabine, abacavir) plus an INSTI (raltegravir); dual NRTIs (tenofovir, emtricitabine) plus dual PIs (darunavir, ritonavir) plus an NNRTI (etravirine); single NRTI (emtricitabine), single NNRTI (etravirine), and dual PIs (darunavir and ritonavir); single NRTI (abacavir), single NNRTI (efavirenz), and single PI (saquinavir). No participants were taking chemokine-receptor antagonists (e.g., maraviroc). Sixteen HIV-uninfected participants were used as controls (56% male, age, 30 [28, 40] ). HIV-infected participants were older compared to uninfected participants (P < 0.001). The study was approved by the University of Hawaii Manoa Committee on Human Studies and participants gave informed consent.
Antagonists
Cenicriviroc, the CCR2 and CCR5 dual antagonist, was obtained USA). VE-cadherin was visualized using a cy3 labeled anti-mouse secondary antibody (Abcam) and the actin cytoskeleton was labeled using a phalloidin probe (Alexa488; Invitrogen, Carlsbad, USA). Immunofluorescence images were acquired using an Axiovert microscope (Zeiss, Germany). 
Electric cell substrate impedance-sensing (ECIS)
Trans-endothelial migration assay
HAoECs, which were not activated or stimulated, were seeded on the top of 24-well 5 m transwell filters and allowed to reach confluency 
CCR2 and CCR5 expression on HAoECs
Flow cytometry
HAoECs were grown to confluency as described above. HAoECs were then scrapped off the tissue culture plate and stained with Live/Dead R Fixable Yellow Dead Cell Stain (YARD) for 15 min at room temperature followed by two, 10 min sequential incubations with anti-CCR2 (PE) and CCR5 (AlexaFluor700) at 37 • C and lastly a 30 min room temperature incubation. 61 Cells were fixed with 1%
PFA and data were acquired on a custom 4-laser BD LSRFortessa (BD Bioscience, San Jose, USA). Compensation and gating analyses were performed using FlowJo (FlowJo LCC, Ashland, USA). All antibodies were purchased from Biolegend (San Diego, USA), except for
Live/Dead Stain (Invitrogen).
Western blot
HAoECs were grown to confluency as described above. Cell lysates were obtained using RIPA buffer with addition of protease and phosphatase inhibitors. Fifteen micrograms of protein was loaded onto an 10% SDS-PAGE gel (Novex NuPAGE, Invitrogen) and transferred to a low fluorescence-PVDF membrane (EMD Millipore, Temecula, USA).
Blocking was carried out using the Odyssey Blocking Buffer (Licor, 
CCR2 and CCR5 expression on monocytes by flow cytometry
Cryopreserved PBMCs were placed in 96 well polypropylene round bottom plates and stained with Live/Dead R Fixable Red Dead Cell Stain for 15 min at room temperature followed by two, 10 min sequential incubations with anti-CCR2 (AlexaFluor647) and CCR5 (PE) at 37 • C. 61 Cells were then stained at room temperature for 30 min 
HAoEC surface adhesion molecule levels
Receptors involved in trans-endothelial migration were measured on HAoECs. Confluent HAoECs were incubated with CVC for 1 h at 37 
Statistical analysis
Clinical data are presented as the median and interquartile range (IQR) 
RESULTS
Direct effects of BMS-22, MVC or CVC on endothelial cell barrier integrity
Endothelial barrier integrity was assessed to ensure that differences in migratory rates between antagonists were not due to disruption of the endothelial monolayer. Inter-endothelial adherence junctions, visualized by VE-cadherin immunofluorescence, were not compromised by any of the antagonist treatments (Fig. 1A) . Endothelial barrier integrity, assessed by electric cell-substrate-impedance sensing, was also not altered due to antagonist treatment, even at concentrations 10 times higher than the experimentally used concentration of 1 M (Fig. 1B) . These experiments demonstrate that observed changes in trans-endothelial migration after treatment with CCR2/CCR5
antagonists were not due to disruption of the endothelial monolayer.
CVC decreases monocyte trans-endothelial migration in both HIV-infected and HIV-uninfected donors
The trans-endothelial migration studies were performed in 3 different ways to assess the independent effects of CKR blockade on the various cell populations in the assay: (A) treatment of HAoEC monolayer only ( Fig. 2A) , (B) treatment of monocytes only (Fig. 2B) , or (C) simultaneous treatment of HAoECs and monocytes (Fig. 2C) . The data are also shown in Supplemental Fig. 1 to better highlight the comparison between HIV-infected and HIV-uninfected migratory rates.
In the absence of antagonist (vehicle alone), monocytes from HIVinfected individuals migrated at significantly higher rates than monocytes from HIV-uninfected persons (migratory factor of 1.44% vs.
0.86%; Supplemental Fig. 1 ). These data indicate that atherosclerosis development may occur at greater rates in HIV-infection due to increased monocyte trans-endothelial migration. (Fig. 2C) . MVC did not alter monocyte trans-endothelial migration (Fig. 2C ). These data indicate that: (1) the inhibitory effect of CVC on the endothelium appears critical in modulating trans-endothelial monocyte migration and (2) dual CKR blockade is more efficient in inhibiting trans-endothelial monocyte migration than single CKR targeting.
Expression levels of CCR2 and CCR5 on primary human aortic endothelial cells and monocytes
To confirm the presence of CVC targets (CCR2 and CCR5) on HAoECs, protein levels for both CKRs were assessed by flow cytometry and Western blotting (Fig. 3A) . CCR2 and CCR5 were detected in the HAoECs samples albeit at relatively low levels (Fig. 3A) . To assess whether the differences in migratory rates between HIV-infected and HIV-uninfected persons were due to varying CCR2 and CCR5 levels on monocytes, we measured CKR cell surface expression by flow cytometry (Fig. 3B ). CCR2 cell surface expression was significantly lower on non-classical monocytes from HIV-infected individuals compared to HIV-uninfected controls (P = 0.005, Fig. 3B ). There were no significant differences in CCR2 levels on classical or intermediate monocytes nor were there any differences in CCR5 on all 3 monocyte subsets (Fig. 3B ). These data suggest that higher migratory rates observed in the HIV-infected groups were not due to higher CCR2 levels.
F I G U R E 2
Trans-endothelial monocyte migration. Pre-migration treatment with antagonist under three conditions: human aortic endothelial cells (HAoECs) only (A), monocytes only (B) or HAoECs and monocytes (C). MCP-1 induced monocyte migration, presented as a monocyte migration factor by dividing the number of migrated monocytes by the number of monocytes pre-migration and expressing it as a percentage, is shown for HIV-uninfected (white circles) and HIV-infected (grey circles) for vehicle, BMS-22, maraviroc (MVC), and cenicriviroc (CVC). The hash mark indicates the mean and error bars are the standard deviations. *P < 0.05; **P < 0.01; ***P < 0.001
CVC treatment selectively decreases E-selectin and PECAM levels on HAoECs
To 
CVC decreases monocyte migration from HIV-infected donors in a chemotaxis assay
Given that we did not observe inhibition of monocyte migration in the trans-endothelial assay, we investigated whether CVC had the capacity to inhibit monocyte mobilization in a chemotaxis assay. For this study, we used a Boyden chamber with a porous membrane devoid of endothelial cells (for details see Supplemental Materials and Methods). Under MCP-1 pressure, we examined monocyte Table 1 ). Classical monocytes, which express relatively high levels of CCR2 (Fig. 3) , had the highest migratory rates toward the CCR2 gradient (Supplemental Fig. 5B ). Non-classical monocytes (low CCR2 expressers; Fig. 3 ) mobilized, albeit less, toward MCP-1 and intermediate monocytes (high CCR2 expressing cells) migrated very little (Supplemental Fig. 5C ). In HIV-infected participants, CVC significantly inhibited total and classical monocyte migration compared to their respective vehicle controls (migratory factor for total monocytes: 2.34% vs. 3.88%; P < 0.0001 and migratory factor for classical monocytes: 0.33% vs. 0.46%; P = 0.003), with no effect on intermediate or non-classical monocyte migration (Supplemental Fig. 5 ).
In HIV-infected donors, BMS-22 and MVC did not inhibit MCP-1-driven migration (Supplemental Fig. 5 ). In fact, when examining total monocyte migratory factors, monocytes incubated with CVC migrated significantly less than cells incubated with BMS-22 (migratory factor: 4.45%; P = 0.0013 or MVC migratory factor: 4.84%; P = 0.0002; Supplemental Fig. 5A ). In HIV-uninfected controls, monocyte migration was not inhibited by any of the CKR antagonists (Supplemental Fig. 5 ). These data suggest that CVC has the potential to inhibit monocyte mobilization.
DISCUSSION
Cardiovascular disease is reportedly the second highest cause of death in the aging HIV-infected population. 62, 63 Understanding the mechanism and finding novel treatment strategies to prevent or improve CVD are thus warranted. We sought to assess the use of the dual CCR2/CCR5 antagonist, CVC, on inhibiting monocyte mobilization toward a CCR2 chemokine gradient in a trans-endothelial migration model, using the single CCR2 and CCR5 antagonists, BMS-22 and MVC, as controls. To our knowledge, this is the first study, in the context of HIV, to utilize HAoECs which is paramount to mimic as closely as possible cellular transmigration that occurs in clinically relevant anatomical sites of atherosclerosis. We chose MCP-1 as the chemotactic agent because this chemokine is a central monocyte chemoattractant and because it is important in cardiovascular disease outcome in HIV-infection as plasma MCP-1 levels are elevated in HIV-associated atherosclerosis. 64, 65 The main finding of this trans-endothelial migration study is that CVC inhibited monocyte transmigration better than BMS-22 or MVC, indicating that blocking CCR2 and CCR5 simultaneously is more effective than a single CCR2 or CCR5 blockade.
Surprisingly, in the trans-endothelial migration model, CVC inhibited monocyte migration when CCR2 and CCR5 were targeted exclusively on the HAoECs. Our results suggest this effect was mediated by decreasing E-selectin cell surface expression, which we speculate may be beneficial in the context of atherogenesis as E-selectin has been detected in human atherosclerosis-prone endothelial cells as well as on the surface of fibrous and lipid-containing human plaques. 66 Therapeutic targeting of E-selectin in the context of inhibiting metastasis is being explored and this strategy could potentially be employed in the setting of atherosclerosis. Glycomimetic E-selectin inhibitors (GMI-1271 and GMI-1359 [a dual E-selectin and CXCR4 inhibitor]), in combination with standard chemotherapy, have been shown to reduce metastatic lesions and improve survival in xenograft mouse models of cancers. [67] [68] [69] [70] Moreover, the E-selectin inhibitor, GMI-1271, which has been shown to be well tolerated in healthy individuals, 71 is currently being evaluated in combination with standard agents to treat acute The mechanism by which CVC influences E-selectin expression is unclear. Inflammatory cytokines, such as tumor necrosis factor-(TNF-) or interleukin (IL)-1 , can transiently activate the endothelium and induce cell surface expression of E-selectin. 72 Although in our cell culture system MCP-1 did not significantly increase E-selectin levels, blocking MCP-1/CCR2 interactions may have inhibited signaling that maintains E-selectin levels at the HAoEC surface. Decreases in cell surface E-selectin could have potentially been due to shedding from the cell membrane 72, 73 or endocytosis of the receptor, where it localizes in lysosomal compartments and is degraded. 72, 74, 75 We measured soluble E-selectin in the supernatant of the HAoEC culture wells using ELISA but levels were below the limit of detection of the assay (data not shown). Given that TNF-stimulation of HUVECs can trigger E-selectin internalization in a matter of hours 72, 74, 75 ; it is conceivable that endocytosis is occurring in our model. Moreover, the interaction of E-selectin with monocytes occurs via P- Our trans-endothelial migration data are similar to reports that monocytes, infected with HIV in vitro, cross in vitro blood brain barrier models more readily than uninfected monocytes. 80, 81 This is in contrast with another trans-endothelial migration model where Westhorpe et al. reported no difference in migration between monocytes infected with HIV in vitro and uninfected monocytes. 82 The discrepancies in results may be due to the Westhorpe study utilizing human umbilical vein endothelial cells compared to HAoECs in our case. 82 Our study offers more physiologically relevant insight into HIV-associated atherosclerosis as firstly, the monocytes from this model were isolated from HIV-infected individuals rather than being infected in vitro and secondly, the source of the endothelial monolayer was from human aorta. Taken together our data may suggest that one of the first steps of atherosclerosis development, namely monocyte trans-endothelial migration, is altered in HIV-infected individuals and therefore could explain the accelerated atherosclerosis development in HIV. Given that our HIV-uninfected group was younger, we must consider age may have also been a factor. 83 Although in vitro HIV-infection of monocytes has been shown to increase CCR2 cell surface expression and enhance the capacity of the monocytes to transmigrate across a BBB model toward 
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